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:   randomized controlled trial
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SG

:   sleeve gastrectomy
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:   type 2 diabetes mellitus

1. INTRODUCTION {#obr13011-sec-0002}
===============

As a direct consequence of the obesity epidemic, the prevalence of obesity‐related comorbidities, including type 2 diabetes mellitus (T2DM), has increased. Between 1980 and 2014, the number of adults with diabetes increased fourfold, from 108 million to 422 million.[1](#obr13011-bib-0001){ref-type="ref"} For the individual, T2DM is associated with reduced quality of life, stigma, increased medical expenses, and risk of diabetes‐related microvascular complications.[2](#obr13011-bib-0002){ref-type="ref"}, [3](#obr13011-bib-0003){ref-type="ref"} In addition, T2DM and its complications impose a substantial burden on society in terms of increased health care costs, reduced productivity, either inability to work or work absenteeism, and lost productive capacity because of early mortality.[4](#obr13011-bib-0004){ref-type="ref"}

Bariatric surgery is an effective treatment option for patients with obesity and T2DM, and the superiority of surgery over medical care for glycaemic control has been demonstrated in several randomized controlled trials (RCTs) and cohort studies.[5](#obr13011-bib-0005){ref-type="ref"}, [6](#obr13011-bib-0006){ref-type="ref"}, [7](#obr13011-bib-0007){ref-type="ref"}, [8](#obr13011-bib-0008){ref-type="ref"}, [9](#obr13011-bib-0009){ref-type="ref"}, [10](#obr13011-bib-0010){ref-type="ref"} The American Diabetes Association recommends bariatric surgery "as an option to treat T2DM in appropriate surgical candidates with BMI ≥ 40 kg/m^2^ (BMI ≥ 37.5 kg/m^2^ in Asian Americans), regardless of the level of glycemic control or complexity of glucose‐lowering regimens, and in adults with BMI 35.0--39.9 kg/m^2^ (32.5--37.4 kg/m^2^ in Asian Americans) when hyperglycemia is inadequately controlled despite lifestyle and optimal medical therapy".[11](#obr13011-bib-0011){ref-type="ref"} In 2016, more than 100 000 patients with diabetes underwent bariatric surgery, whereof the majority received Roux‐en‐Y gastric bypass (RYGB) or sleeve gastrectomy (SG).[12](#obr13011-bib-0012){ref-type="ref"}, [13](#obr13011-bib-0013){ref-type="ref"}

Improved glycaemic control after bariatric surgery is mainly explained by weight loss. However, even before changes in body weight occur, insulin and glucose levels improve---indicating that some of the hypoglycaemic effects of bariatric surgery may be independent of weight loss.[14](#obr13011-bib-0014){ref-type="ref"} Caloric restriction after surgery is thought to be a driver of this early improved glycaemic homeostasis, but the anatomical alterations of the gut and intestines postoperatively may also be important contributors. RYGB and SG are similar in that both procedures reduce the size of the stomach, but only RYGB includes a bypass of the duodenum and the proximal small intestine. Thus, particularly after RYGB, there is a rapid delivery of undigested food to the small intestine with subsequent increased release of the gut‐derived insulin stimulating the hormone glucagon‐like peptide‐1 (GLP‐1). Moreover, some studies indicate that exclusion of duodenal nutrient exposure is responsible for the weight‐loss--independent effects on glucose homeostasis immediately after RYGB,[15](#obr13011-bib-0015){ref-type="ref"}, [16](#obr13011-bib-0016){ref-type="ref"}, [17](#obr13011-bib-0017){ref-type="ref"}, [18](#obr13011-bib-0018){ref-type="ref"} but the results are inconsistent.[19](#obr13011-bib-0019){ref-type="ref"} Bariatric surgery is also accompanied by changes in other gut‐derived and pancreatic‐derived hormones[20](#obr13011-bib-0020){ref-type="ref"} and changes in the microbial composition,[21](#obr13011-bib-0021){ref-type="ref"} which directly or indirectly may influence glycaemic control.

With bariatric surgery considered a highly effective treatment of T2DM in patients with obesity, a comparison of the effectiveness of the two most commonly performed bariatric procedures on T2DM remission is vital. A recent systematic review of RCTs found diabetes remission rates to favour RYGB at 1, 3, and 5 years, but not significantly.[22](#obr13011-bib-0022){ref-type="ref"} However, this review failed to include two important RCTs,[23](#obr13011-bib-0023){ref-type="ref"}, [24](#obr13011-bib-0024){ref-type="ref"} including the 1‐year results from the landmark STAMPEDE trial. The meta‐analysis was also flawed by duplicate publications, and it did not exclude studies of variants of gastric bypass, such as banded and mini gastric bypass. Another systematic review of RCTs from 2017 suggested that RYGB and SG were equally effective in resolving T2DM in patients with obesity[25](#obr13011-bib-0025){ref-type="ref"} but that further studies were required. Reviews including both RCTs and retrospective studies have concluded that RYGB is associated with better resolution and control of T2DM than SG,[26](#obr13011-bib-0026){ref-type="ref"}, [27](#obr13011-bib-0027){ref-type="ref"}, [28](#obr13011-bib-0028){ref-type="ref"} while one review found no difference between the procedures.[29](#obr13011-bib-0029){ref-type="ref"} However, some important trials were missing from these reviews, and two larger RCTs have recently been published.[30](#obr13011-bib-0030){ref-type="ref"}, [31](#obr13011-bib-0031){ref-type="ref"}

1.1. Objectives {#obr13011-sec-0003}
---------------

This systematic review and meta‐analysis seeks to compare, through the results available from RCTs, the effects of RYGB and SG on remission of T2DM in patients eligible for bariatric surgery.

2. METHODS {#obr13011-sec-0004}
==========

2.1. Protocol and registration {#obr13011-sec-0005}
------------------------------

The protocol of this systematic review was submitted to PROSPERO on 7 October 2019 (see [Data S1](#obr13011-supitem-0001){ref-type="supplementary-material"} for the complete protocol).

2.2. Eligibility criteria {#obr13011-sec-0006}
-------------------------

We included RCTs of adults (18 years and older) eligible for bariatric surgery, comparing the effects of RYGB and SG on remission of T2DM. Studies where either all or some of the study participants had T2DM were included, with studies with follow‐up of less than 1 year excluded.

2.3. Information sources and search strategy {#obr13011-sec-0007}
--------------------------------------------

We performed the search in cooperation with health science librarians with expertise in systematic review searching, using medical subject headings (MeSH) and text words related to T2DM, bariatric surgery, RYGB, and SG (see Table [S1](#obr13011-supitem-0002){ref-type="supplementary-material"} for the complete search strategy). MEDLINE, EMBASE, the Cochrane Central Register of Controlled Trials, and [ClinicalTrials.gov](http://ClinicalTrials.gov) were searched. The literature search was limited to English language and humans. Articles published ahead of print were evaluated, but protocols were not included. The search was restricted to studies published between database inception to 21 November 2019.

2.4. Data collection {#obr13011-sec-0008}
--------------------

The literature search results were uploaded to an Internet‐based review program ([www.covidence.org](http://www.covidence.org)) that facilitates review literature screening and cooperation among the reviewers. Two of the authors (HB and DH) independently screened the abstracts sourced by the search against the inclusion criteria. Full texts for all papers meeting the inclusion criteria were subsequently obtained. Any uncertainty or disagreement between the reviewers was resolved through discussion with a third party (JH).

2.5. Data extraction {#obr13011-sec-0009}
--------------------

We extracted the following data from each study: authors, publication year, country, trial registration number, study design and duration, study population characteristics (number of patients with T2DM, BMI, HbA1c levels), T2DM remission criteria, percentage of participants with diabetes remission in the RYGB and SG groups, and the primary outcomes of the trial. If results according to different remission criteria were given, the Buse\'s consensus group criteria were used if available.[32](#obr13011-bib-0032){ref-type="ref"}

2.6. Risk of bias within individual studies {#obr13011-sec-0010}
-------------------------------------------

Two reviewers (HB and DH) independently evaluated risk of bias within the individual studies using the Cochrane collaborations tool.[33](#obr13011-bib-0033){ref-type="ref"} The risk of selection bias, performance bias, detection bias, attrition bias, reporting bias, and other biases were judged as high, low, or unclear. The reviewers resolved uncertainty and disagreement through discussion and consensus with a third party (JH).

2.7. Statistical analysis {#obr13011-sec-0011}
-------------------------

T2DM remission rates from the individual studies were used to calculate a relative risk (RR) of remission with a 95% confidence interval (CI). Random‐effect models were used to adjust for possible variations in baseline risk between the trials. RRs were calculated according to the intention to treat principle where missing cases were treated as nonremission of T2DM. The studies were grouped into studies with short‐term (1‐year) follow‐up and studies with medium‐term (2‐ to 5‐year) follow‐up. When results from multiple time points in the time frame 2 to 5 years were reported from the same cohort, results from the latest time point were reported. The Cochrane *Q* test was used to assess between‐study heterogeneity, and the magnitude of heterogeneity was evaluated by the *I* ^2^ statistics. *I* ^2^ values of 25%, 50%, and 75% were regarded as low, moderate, and high heterogeneity, respectively.[34](#obr13011-bib-0034){ref-type="ref"} Sensitivity analyses and subgroup analyses were subsequently performed. Publication bias was assessed by visual inspection of funnel plots and the Egger test.

Statistical analyses were performed using Review manager 5.3 and STATA/MP 14.2. *P* values less than .05 were considered statistically significant.

2.8. Quality of evidence {#obr13011-sec-0012}
------------------------

The Grading of Recommendations Assessment, Development and Evaluation (GRADE) was used to assess the overall quality of evidence for the included RCTs.[35](#obr13011-bib-0035){ref-type="ref"} Evidence was downgraded from "high quality" by one level in case of serious (or by two for very serious) study limitations (risk of bias), indirectness of evidence, serious inconsistency, imprecision of effect estimates, or potential publication bias.

3. RESULTS {#obr13011-sec-0013}
==========

3.1. Study selection {#obr13011-sec-0014}
--------------------

The literature search identified 2650 unique citations, whereof 2625 were excluded because of irrelevant content, duplication, or non‐English language (Figure [1](#obr13011-fig-0001){ref-type="fig"}). Of the 25 studies that were full‐text screened, 13 did not meet the inclusion criteria either because follow‐up time was too short,[36](#obr13011-bib-0036){ref-type="ref"}, [37](#obr13011-bib-0037){ref-type="ref"}, [38](#obr13011-bib-0038){ref-type="ref"}, [39](#obr13011-bib-0039){ref-type="ref"} the authors did not differentiate between improvement and remission of T2DM,[40](#obr13011-bib-0040){ref-type="ref"} other bariatric procedures were performed (mini gastric bypass, banded RYGB, and metabolic gastric bypass),[41](#obr13011-bib-0041){ref-type="ref"}, [42](#obr13011-bib-0042){ref-type="ref"}, [43](#obr13011-bib-0043){ref-type="ref"}, [44](#obr13011-bib-0044){ref-type="ref"} the study was not an RCT,[45](#obr13011-bib-0045){ref-type="ref"} no patients in the SG‐group had T2DM,[46](#obr13011-bib-0046){ref-type="ref"} or the study included a subpopulation of an already included RCT.[47](#obr13011-bib-0047){ref-type="ref"} We detected two studies that had been performed in the same study population,[48](#obr13011-bib-0048){ref-type="ref"}, [49](#obr13011-bib-0049){ref-type="ref"} and of these, only the study referring to a clinical trial registry number was included.[48](#obr13011-bib-0048){ref-type="ref"} Finally, 12 articles of 10 different RCTs,[5](#obr13011-bib-0005){ref-type="ref"}, [23](#obr13011-bib-0023){ref-type="ref"}, [24](#obr13011-bib-0024){ref-type="ref"}, [30](#obr13011-bib-0030){ref-type="ref"}, [31](#obr13011-bib-0031){ref-type="ref"}, [48](#obr13011-bib-0048){ref-type="ref"}, [50](#obr13011-bib-0050){ref-type="ref"}, [51](#obr13011-bib-0051){ref-type="ref"}, [52](#obr13011-bib-0052){ref-type="ref"}, [53](#obr13011-bib-0053){ref-type="ref"}, [54](#obr13011-bib-0054){ref-type="ref"}, [55](#obr13011-bib-0055){ref-type="ref"} where of four had data on remission at different lengths of follow‐up, were included in the systematic review.

![Flow diagram](OBR-21-e13011-g001){#obr13011-fig-0001}

3.2. Study characteristics {#obr13011-sec-0015}
--------------------------

The 10 studies comprised 705 patients with T2DM, with the majority including patients with BMI ≥ 35 kg/m^2^ (Table [1](#obr13011-tbl-0001){ref-type="table"}). However, the STAMPEDE trial and two studies from Chinese populations[5](#obr13011-bib-0005){ref-type="ref"}, [23](#obr13011-bib-0023){ref-type="ref"}, [54](#obr13011-bib-0054){ref-type="ref"}, [55](#obr13011-bib-0055){ref-type="ref"} also included patients with BMI \< 35 kg/m^2^, where of one[55](#obr13011-bib-0055){ref-type="ref"} had only recruited patients with BMI ≤ 35 kg/m^2^. Half of the patients (n = 352) underwent RYGB, while the remaining half (n = 353) underwent SG. Five trials[5](#obr13011-bib-0005){ref-type="ref"}, [23](#obr13011-bib-0023){ref-type="ref"}, [24](#obr13011-bib-0024){ref-type="ref"}, [31](#obr13011-bib-0031){ref-type="ref"}, [54](#obr13011-bib-0054){ref-type="ref"}, [55](#obr13011-bib-0055){ref-type="ref"} included only patients with T2DM, and these five had complete remission of T2DM (HbA1c \< 6.0% or HbA1c ≤ 6.0%) as the primary or secondary endpoint. The remaining trials had weight loss as the main outcome and remission of T2DM as a secondary or exploratory outcome. However, in two trials,[30](#obr13011-bib-0030){ref-type="ref"}, [50](#obr13011-bib-0050){ref-type="ref"} only data on partial T2DM remission were given. Length of follow‐up was in the time frame 1 to 5 years, and four trials[5](#obr13011-bib-0005){ref-type="ref"}, [23](#obr13011-bib-0023){ref-type="ref"}, [30](#obr13011-bib-0030){ref-type="ref"}, [51](#obr13011-bib-0051){ref-type="ref"}, [52](#obr13011-bib-0052){ref-type="ref"}, [53](#obr13011-bib-0053){ref-type="ref"} included data on both short‐ and medium‐term follow‐up. Sample sizes ranged from 10 to 120 patients, with all but two studies[51](#obr13011-bib-0051){ref-type="ref"}, [52](#obr13011-bib-0052){ref-type="ref"}, [53](#obr13011-bib-0053){ref-type="ref"} single‐centre studies, and all the studies were performed in either Europe, Asia, or the United States. One[30](#obr13011-bib-0030){ref-type="ref"} of the two authors contacted in order to clarify data responded to this request.

###### 

Characteristics of the included trials

<table><thead><tr class="header"><th style="text-align: left;">Authors</th><th style="text-align: left;">Registration</th><th style="text-align: left;">Country</th><th style="text-align: left;">Study Design</th><th style="text-align: left;">Duration</th><th style="text-align: left;">Percent of Patients with T2DM</th><th style="text-align: left;">Number of Patients with T2DM</th><th style="text-align: left;">Age, y<a href="#obr13011-note-0002" data-ref-type="fn">a</a></th><th style="text-align: left;">BMI, kg/m<sup>2</sup> <a href="#obr13011-note-0002" data-ref-type="fn">a</a></th><th style="text-align: left;">HbA1c, %<a href="#obr13011-note-0002" data-ref-type="fn">a</a></th><th style="text-align: left;">T2DM Remission Criteria</th><th style="text-align: left;">Primary Endpoint</th></tr></thead><tbody><tr class="odd"><td style="text-align: left;">Hofsø 2019 <a href="#obr13011-bib-0031" data-ref-type="ref">31</a></td><td style="text-align: left;">NCT01778738</td><td style="text-align: left;">Norway</td><td style="text-align: left;">Single‐centre, triple‐blinded RCT comparing RYGB and sleeve</td><td style="text-align: left;">1 year</td><td style="text-align: left;">100</td><td style="text-align: left;"><p><strong>RYGB:</strong> 54</p><p><strong>Sleeve:</strong> 55</p></td><td style="text-align: left;"><strong>RYGB</strong> <strong>:</strong> 48.2 (8.9) <strong>Sleeve:</strong> 47.1 (10.2)</td><td style="text-align: left;"><strong>RYGB</strong> <strong>:</strong> 42.4 (5.4) <strong>Sleeve:</strong> 42.1 (5.3)</td><td style="text-align: left;"><strong>RYGB</strong> <strong>:</strong> 7.6 (6.8‐8.5) <a href="#obr13011-note-0003" data-ref-type="fn">b</a> <strong>Sleeve:</strong> 7.9 (6.9‐9.9)</td><td style="text-align: left;">HbA1c ≤ 6% with no pharmacologic therapy</td><td style="text-align: left;">T2DM remission</td></tr><tr class="even"><td style="text-align: left;">Kalinowski 2017 <a href="#obr13011-bib-0048" data-ref-type="ref">48</a></td><td style="text-align: left;">NCT01806506</td><td style="text-align: left;">Poland</td><td style="text-align: left;">Single‐centre, nonblinded, RCT comparing RYGB and sleeve</td><td style="text-align: left;">1 year</td><td style="text-align: left;">36.1</td><td style="text-align: left;"><p><strong>RYGB:</strong> 14</p><p><strong>Sleeve:</strong> 12</p></td><td style="text-align: left;"><p><strong>RYGB</strong> <strong>:</strong> 43.9 (10.8) <a href="#obr13011-note-0004" data-ref-type="fn">c</a></p><p><strong>Sleeve:</strong> 44.9 (10.6) <a href="#obr13011-note-0004" data-ref-type="fn">c</a></p></td><td style="text-align: left;"><p><strong>RYGB</strong> <strong>:</strong> 48.6 (5.4) <a href="#obr13011-note-0004" data-ref-type="fn">c</a></p><p><strong>Sleeve:</strong> 46.1 (5.9) <a href="#obr13011-note-0004" data-ref-type="fn">c</a></p></td><td style="text-align: left;"><p><strong>RYGB</strong> <strong>:</strong> 6.3 (0.9) <a href="#obr13011-note-0004" data-ref-type="fn">c</a></p><p><strong>Sleeve:</strong> 6.4 (1.3) <a href="#obr13011-note-0004" data-ref-type="fn">c</a></p></td><td style="text-align: left;">HbA1c &lt; 6% and fasting glucose &lt;5.6 mmol/L with no pharmacologic therapy</td><td style="text-align: left;">Weight loss</td></tr><tr class="odd"><td style="text-align: left;">Kehagias 2011 <a href="#obr13011-bib-0050" data-ref-type="ref">50</a></td><td style="text-align: left;">‐</td><td style="text-align: left;">Greece</td><td style="text-align: left;">Single‐centre, double‐blinded RCT, comparing RYGB and sleeve</td><td style="text-align: left;">3 years</td><td style="text-align: left;">16.7</td><td style="text-align: left;"><p><strong>RYGB:</strong> 5</p><p><strong>Sleeve:</strong> 5</p></td><td style="text-align: left;"><p><strong>RYGB</strong> <strong>:</strong> 36.0 (8.4) <a href="#obr13011-note-0004" data-ref-type="fn">c</a></p><p><strong>Sleeve:</strong> 33.7 (9.9) <a href="#obr13011-note-0004" data-ref-type="fn">c</a></p></td><td style="text-align: left;"><p><strong>RYGB</strong> <strong>:</strong> 45.8 (3.7) <a href="#obr13011-note-0004" data-ref-type="fn">c</a></p><p><strong>Sleeve:</strong> 44.9 (3.4) <a href="#obr13011-note-0004" data-ref-type="fn">c</a></p></td><td style="text-align: left;"><p><strong>RYGB</strong> <strong>:</strong> NR</p><p><strong>Sleeve:</strong> NR</p></td><td style="text-align: left;">Fasting plasma glucose &lt;126 mg/dL or 2‐h plasma glucose &lt;200 mg/dL during OGTT or no pharmacologic therapy</td><td style="text-align: left;">Weight loss</td></tr><tr class="even"><td style="text-align: left;">Keidar 2013 <a href="#obr13011-bib-0024" data-ref-type="ref">24</a></td><td style="text-align: left;">NCT00667706</td><td style="text-align: left;">Israel</td><td style="text-align: left;">Single‐centre, nonblinded RCT comparing RYGB and sleeve</td><td style="text-align: left;">1 year</td><td style="text-align: left;">100</td><td style="text-align: left;"><p><strong>RYGB:</strong> 22</p><p><strong>Sleeve:</strong> 19</p></td><td style="text-align: left;"><p><strong>RYGB</strong> <strong>:</strong> 51.5 (8.3)</p><p><strong>Sleeve:</strong> 47.7 (11.7)</p></td><td style="text-align: left;"><p><strong>RYGB</strong> <strong>:</strong> 42.0 (4.8)</p><p><strong>Sleeve:</strong> 42.5 (5.2)</p></td><td style="text-align: left;"><p><strong>RYGB</strong> <strong>:</strong> 7.70 (1.3)</p><p><strong>Sleeve:</strong> 8.34 (1.8)</p></td><td style="text-align: left;">Cessation of glucose lowering medication and normal<a href="#obr13011-note-0005" data-ref-type="fn">d</a> HbA1c and glucose levels</td><td style="text-align: left;">HbA1c level change</td></tr><tr class="odd"><td style="text-align: left;">Peterli 2013 <a href="#obr13011-bib-0051" data-ref-type="ref">51</a> and 2018 <a href="#obr13011-bib-0052" data-ref-type="ref">52</a></td><td style="text-align: left;">NCT00356213</td><td style="text-align: left;">Switzerland</td><td style="text-align: left;">Multicentre, nonblinded RCT comparing RYGB and sleeve</td><td style="text-align: left;">1 and 5 years</td><td style="text-align: left;">24.9</td><td style="text-align: left;"><p><strong>RYGB:</strong> 28</p><p><strong>Sleeve:</strong> 26</p></td><td style="text-align: left;"><p><strong>RYGB</strong> <strong>:</strong> 42.1 (11.2) <a href="#obr13011-note-0004" data-ref-type="fn">c</a></p><p><strong>Sleeve:</strong> 43.0 (11.1) <a href="#obr13011-note-0004" data-ref-type="fn">c</a></p></td><td style="text-align: left;"><p><strong>RYGB</strong> <strong>:</strong> 44.2 (5.3) <a href="#obr13011-note-0004" data-ref-type="fn">c</a></p><p><strong>Sleeve:</strong> 43.6 (5.2) <a href="#obr13011-note-0004" data-ref-type="fn">c</a></p></td><td style="text-align: left;"><p><strong>RYGB:</strong> 7.2 (6.4‐8.0)</p><p><strong>SG:</strong> 7.6 (6.8‐8.4)</p></td><td style="text-align: left;"><strong>1 year:</strong> No pharmacologic therapy</td><td style="text-align: left;">Weight loss</td></tr><tr class="even"><td style="text-align: left;"><strong>5 years:</strong> HbA1c &lt; 6% and fasting glucose &lt;100 mg/dL (&lt;5.6 mmol/L) with no pharmacologic therapy for at least 1 year</td><td style="text-align: left;"></td><td style="text-align: left;"></td><td style="text-align: left;"></td><td style="text-align: left;"></td><td style="text-align: left;"></td><td style="text-align: left;"></td><td style="text-align: left;"></td><td style="text-align: left;"></td><td style="text-align: left;"></td><td style="text-align: left;"></td><td style="text-align: left;"></td></tr><tr class="odd"><td style="text-align: left;">Ruiz‐Tovar 2018 <a href="#obr13011-bib-0030" data-ref-type="ref">30</a></td><td style="text-align: left;"><a href="http://clinicaltrials.gov/show/NCT03467646">NCT03467646</a></td><td style="text-align: left;">Spain</td><td style="text-align: left;">Single‐centre, nonblinded RCT comparing RYGB, sleeve and one‐anastomosis gastric bypass</td><td style="text-align: left;">1 and 5 years</td><td style="text-align: left;">31.7</td><td style="text-align: left;"><p><strong>RYGB:</strong> 59</p><p><strong>Sleeve:</strong> 61</p></td><td style="text-align: left;"><p><strong>RYGB</strong> <strong>:</strong> 45.0 (11.3) <a href="#obr13011-note-0004" data-ref-type="fn">c</a></p><p><strong>Sleeve:</strong> 43.9 (10.9) <a href="#obr13011-note-0004" data-ref-type="fn">c</a></p></td><td style="text-align: left;"><p><strong>RYGB</strong> <strong>:</strong> 45.3 (3.2) <a href="#obr13011-note-0004" data-ref-type="fn">c</a></p><p><strong>Sleeve:</strong> 46.5 (3.4) <a href="#obr13011-note-0004" data-ref-type="fn">c</a></p></td><td style="text-align: left;"><p><strong>RYGB</strong> <strong>:</strong> NR</p><p><strong>Sleeve:</strong> NR</p></td><td style="text-align: left;">Plasma glucose below 110 mg/dL (6.1 mmol/L) and HbA1c below 6.5% with no pharmacologic therapy</td><td style="text-align: left;">Weight loss</td></tr><tr class="even"><td style="text-align: left;">Salminen 2018 <a href="#obr13011-bib-0053" data-ref-type="ref">53</a></td><td style="text-align: left;"><a href="http://clinicaltrials.gov/show/NCT00793143">NCT00793143</a></td><td style="text-align: left;">Finland</td><td style="text-align: left;">Multi‐centre, nonblinded RCT comparing RYGB and sleeve</td><td style="text-align: left;">1 and 5 years</td><td style="text-align: left;">42.1</td><td style="text-align: left;"><p><strong>RYGB:</strong> 49</p><p><strong>Sleeve:</strong> 52</p></td><td style="text-align: left;"><p><strong>RYGB</strong> <strong>:</strong> 48.4 (9.3) <a href="#obr13011-note-0004" data-ref-type="fn">c</a></p><p><strong>Sleeve:</strong> 48.5 (9.6) <a href="#obr13011-note-0004" data-ref-type="fn">c</a></p></td><td style="text-align: left;"><p><strong>RYGB:</strong> 47.4 (45.8‐49.0)</p><p><strong>SG:</strong> 46.3 (44.7‐47.9)</p></td><td style="text-align: left;"><p><strong>RYGB</strong> <strong>:</strong> 7.2 (7.0‐7.5)</p><p><strong>SG</strong> <strong>:</strong> 7.2 (7.0‐7.5)</p></td><td style="text-align: left;"><strong>1 year:</strong> No pharmacologic therapy</td><td style="text-align: left;">Weight loss</td></tr><tr class="odd"><td style="text-align: left;"><strong>5 years:</strong> HbA1c &lt; 6% and fasting glucose &lt;100 mg/dL (&lt;5.6 mmol/L) with no pharmacologic therapy for at least 1 year</td><td style="text-align: left;"></td><td style="text-align: left;"></td><td style="text-align: left;"></td><td style="text-align: left;"></td><td style="text-align: left;"></td><td style="text-align: left;"></td><td style="text-align: left;"></td><td style="text-align: left;"></td><td style="text-align: left;"></td><td style="text-align: left;"></td><td style="text-align: left;"></td></tr><tr class="even"><td style="text-align: left;">Schauer 2012 <a href="#obr13011-bib-0023" data-ref-type="ref">23</a> and 2017 <a href="#obr13011-bib-0005" data-ref-type="ref">5</a></td><td style="text-align: left;">NCT00432809</td><td style="text-align: left;">USA</td><td style="text-align: left;">Single‐centre, nonblinded, RCT comparing intensive medical therapy alone or intensive medical therapy combined with either RYGB or sleeve gastrectomy</td><td style="text-align: left;">1 and 5 years</td><td style="text-align: left;">100</td><td style="text-align: left;"><p><strong>RYGB:</strong> 50</p><p><strong>Sleeve:</strong> 50</p></td><td style="text-align: left;"><p><strong>RYGB</strong> <strong>:</strong> 48.3 (8.4)</p><p><strong>Sleeve:</strong> 47.9 (8.0)</p></td><td style="text-align: left;"><p><strong>RYGB</strong> <strong>:</strong> 37.0 (3.3)</p><p><strong>Sleeve:</strong> 36.2 (3.9)</p></td><td style="text-align: left;"><p><strong>RYGB:</strong> 9.3 (1.5)</p><p><strong>SG</strong>: 9.5 (1.7)</p></td><td style="text-align: left;">HbA1c ≤ 6% without pharmacologic therapy</td><td style="text-align: left;">Glycated haemoglobin level ≤ 6.0% with or without the use of pharmacologic therapy</td></tr><tr class="odd"><td style="text-align: left;">Tang 2016 <a href="#obr13011-bib-0054" data-ref-type="ref">54</a></td><td style="text-align: left;">‐</td><td style="text-align: left;">China</td><td style="text-align: left;">Single‐centre, nonblinded, RCT comparing RYGB and sleeve</td><td style="text-align: left;">2 years</td><td style="text-align: left;">100</td><td style="text-align: left;"><p><strong>RYGB:</strong> 40</p><p><strong>Sleeve:</strong> 40</p></td><td style="text-align: left;"><p><strong>RYGB</strong> <strong>:</strong> 40.4 (12.3)</p><p><strong>Sleeve:</strong> 36.6 (8.0)</p></td><td style="text-align: left;"><p><strong>RYGB</strong> <strong>:</strong> 37.8 (5.6)</p><p><strong>Sleeve:</strong> 38.4 (8.6)</p></td><td style="text-align: left;"><p><strong>RYGB</strong> <strong>:</strong> 7.4 (1.8)</p><p><strong>SG</strong> <strong>:</strong> 7.4 (1.8)</p></td><td style="text-align: left;">HbA1c &lt; 6% and fasting glucose &lt;100 mg/dL (&lt;5.6 mmol/L) with no pharmacologic therapy for at least 1 year</td><td style="text-align: left;">Partial remission and complete remission of T2DM</td></tr><tr class="even"><td style="text-align: left;">Yang 2015 <a href="#obr13011-bib-0055" data-ref-type="ref">55</a></td><td style="text-align: left;">‐</td><td style="text-align: left;">China</td><td style="text-align: left;">Single‐centre, nonblinded, RCT comparing RYGB and sleeve gastrectomy</td><td style="text-align: left;">3 years</td><td style="text-align: left;">100</td><td style="text-align: left;"><p><strong>RYGB:</strong> 32</p><p><strong>Sleeve:</strong> 32</p></td><td style="text-align: left;"><p><strong>RYGB</strong> <strong>:</strong> 41.4 (9.3)</p><p><strong>Sleeve:</strong> 40.4 (9.4)</p></td><td style="text-align: left;"><p><strong>RYGB</strong> <strong>:</strong> 32.3 (2.4)</p><p><strong>Sleeve:</strong> 31.8 (3.0)</p></td><td style="text-align: left;"><p><strong>RYGB:</strong> 8.9 (1.3)</p><p><strong>SG:</strong> 8.5 (1.2)</p></td><td style="text-align: left;">HbA1c &lt; 6.0% and fasting glucose &lt;7.0 mmol/L with no pharmacologic therapy</td><td style="text-align: left;">T2DM remission</td></tr></tbody></table>

Abbreviations: BMI, body mass index; NR, not reported; OGTT, oral glucose tolerance test; RCT, randomized controlled trial; RYGB, Roux‐en‐Y gastric bypass; SG, sleeve gastrectomy, T2DM, type 2 diabetes mellitus.

Mean (SD) or (95% CI) unless otherwise stated.

Median (interquartile range).

For the total population---not only the patients with T2DM.

Level not reported.

3.3. Risk of bias {#obr13011-sec-0016}
-----------------

Risk of bias within the individual studies is shown in Figure [2](#obr13011-fig-0002){ref-type="fig"}. All studies, except for one,[54](#obr13011-bib-0054){ref-type="ref"} had adequately described the method of randomization. Methods of allocation concealment were properly described in half[5](#obr13011-bib-0005){ref-type="ref"}, [23](#obr13011-bib-0023){ref-type="ref"}, [31](#obr13011-bib-0031){ref-type="ref"}, [50](#obr13011-bib-0050){ref-type="ref"}, [51](#obr13011-bib-0051){ref-type="ref"}, [52](#obr13011-bib-0052){ref-type="ref"}, [53](#obr13011-bib-0053){ref-type="ref"} of the included trials*,* and only two studies[31](#obr13011-bib-0031){ref-type="ref"}, [50](#obr13011-bib-0050){ref-type="ref"} were blinded (participants and study personnel), whereof one[31](#obr13011-bib-0031){ref-type="ref"} was triple blinded (participants, study personnel, and data analyser). All included studies were regarded as having low risk of attrition bias. Four studies were either not registered[50](#obr13011-bib-0050){ref-type="ref"}, [54](#obr13011-bib-0054){ref-type="ref"}, [55](#obr13011-bib-0055){ref-type="ref"} or registered after completion of the trial[30](#obr13011-bib-0030){ref-type="ref"} and were thus regarded as having high risk of reporting bias. One study[24](#obr13011-bib-0024){ref-type="ref"} was considered to be at high risk of other biases because of deviation from the study protocol reported on Clinical Trials (NCT00667706). A summary of the percentage of trials that were at low, unclear, and high risk of bias for the different domains is shown in Figure [3](#obr13011-fig-0003){ref-type="fig"}.

![Risk of bias summary](OBR-21-e13011-g002){#obr13011-fig-0002}

![Risk of bias graph](OBR-21-e13011-g003){#obr13011-fig-0003}

3.4. Results from meta‐analyses {#obr13011-sec-0017}
-------------------------------

### 3.4.1. Short‐term follow‐up {#obr13011-sec-0018}

Among the seven studies that compared the effects of RYGB and SG on remission of T2DM at 1 year, the remission rate was higher among patients undergoing RYGB (156/276, 57%) compared with those undergoing SG (128/275, 47%), RR (95% CI) 1.20 (1.00‐1.45), *P* = .047, and the heterogeneity between the studies was low (*I* ^2^ = 24.9%, *P* = .239, moderate‐quality evidence) (Figure [4](#obr13011-fig-0004){ref-type="fig"}, Table [2](#obr13011-tbl-0002){ref-type="table"}).

![Comparing the effects of Roux‐en‐Y gastric bypass (RYGB) and sleeve gastrectomy (SG) on remission of type 2 diabetes mellitus (T2DM) in studies with short‐term follow‐up](OBR-21-e13011-g004){#obr13011-fig-0004}

###### 

Quality of evidence and summary of findings

  Certainty Assessment                                    Summary of Findings                                                                                                                                                                                                                                                                              
  ------------------------------------------------------- ------------------------------------------------ --------------- --------------------------- ------------------------------------------------ ------------------ ------------------------------- ---------------------- -------------------------- ------------------------------ -------------- -------------------------------------------------
  No. of Participants (Studies) Follow‐Up                 Risk of Bias                                     Inconsistency   Indirectness                Imprecision                                      Publication Bias   Overall Certainty of Evidence   Study Event Rates, %   Relative Effect (95% CI)   Anticipated Absolute Effects                  
  With SG                                                 With RYGB                                        Risk with SG    Risk Difference with RYGB                                                                                                                                                                                                       
  **Remission of T2DM (follow‐up: 1 year)**                                                                                                                                                                                                                                                                                                                
  551 (7 RCTs)                                            Serious[a](#obr13011-note-0007){ref-type="fn"}   Not serious     Not serious                 Not serious                                      None               Moderate                        128/275 (46.5%)        156/276 (56.5%)            **RR 1.20** (1.00 to 1.45)     465 per 1000   **93 more per 1000** (from 0 fewer to 209 more)
  **Remission of T2DM (follow‐up: range 2 to 5 years)**                                                                                                                                                                                                                                                                                                    
  529 (7 RCTs)                                            Serious[b](#obr13011-note-0008){ref-type="fn"}   Not serious     Not serious                 Serious[c](#obr13011-note-0009){ref-type="fn"}   None               Low                             121/266 (45.5%)        132/263 (50.2%)            **RR 1.06** (0.94 to 1.20)     455 per 1000   **27 more per 1000** (from 27 fewer to 91 more)

Abbreviations: CI**,** confidence interval; RCT, randomized controlled trial; RR**,** risk ratio; RYGB, Roux‐en‐Y gastric bypass; SG, sleeve gastrectomy, T2DM, type 2 diabetes mellitus.

See risk of bias figure.

See risk of bias figure.

The 95% CI overlaps no effect.

When excluding the two studies[24](#obr13011-bib-0024){ref-type="ref"}, [30](#obr13011-bib-0030){ref-type="ref"} with high risk of bias in three domains, the effect estimate increased, RR (95% CI) 1.38 (1.12‐1.70), *P* = .0023, in favour of RYGB. One of the studies[30](#obr13011-bib-0030){ref-type="ref"} with high risk of bias was heavily weighted (38.8%), and removal of this study from the analysis resulted in an effect estimate of 1.33 (1.09‐1.64), *P* = .0056. In addition, after restricting the analysis to studies that only included patients with T2DM,[23](#obr13011-bib-0023){ref-type="ref"}, [24](#obr13011-bib-0024){ref-type="ref"}, [31](#obr13011-bib-0031){ref-type="ref"} the effect estimate (RR) increased: 1.39 (0.94‐2.07), *P* = .10.

There was no indication of publication bias as the funnel plot was satisfactory, and the Egger test indicated that there was no small‐study effect (*P* = .62).

### 3.4.2. Medium‐term follow‐up {#obr13011-sec-0019}

Seven studies reported data on remission of T2DM 2 to 5 years after bariatric surgery. The overall estimate showed that the remission rates were 132/263 (50%) in the RYGB group and 121/266 (46%) in the SG group, with no significant between‐group difference, RR (95% CI) 1.06 (0.94‐1.20), *P* = .34, and no heterogeneity between the studies, *I* ^2^ = 0.0%, *P* = .70, low‐quality evidence (Figure [5](#obr13011-fig-0005){ref-type="fig"}, Table [2](#obr13011-tbl-0002){ref-type="table"}).

![Comparing the effects of Roux‐en‐Y gastric bypass (RYGB) and sleeve gastrectomy (SG) on remission of type 2 diabetes mellitus (T2DM) in studies with medium‐term follow‐up](OBR-21-e13011-g005){#obr13011-fig-0005}

Excluding the studies judged as being at high risk of bias in at least three domains did not alter the overall effect estimate: 1.19 (0.89‐1.60), *P* = .25. Three studies included only patients with T2DM, and a subgroup analysis of these studies provided an effect estimate of 1.03 (0.79‐1.34), *P* = .830.

There was no indication of publication bias as the funnel plot was satisfactory, and the Egger test indicated no small‐study effect (*P* = .26).

4. DISCUSSION {#obr13011-sec-0020}
=============

4.1. Summary of main results {#obr13011-sec-0021}
----------------------------

The current systematic review and meta‐analysis compared the effect of RYGB and SG on remission of T2DM in patients with overweight or obesity. Ten different RCTs were included, and the estimates showed that the likelihood of remission was 20% higher among patients undergoing RYGB (57%) compared with SG (47%) 1 year after surgery, but the remission rates did not differ significantly between the surgical procedures 2 to 5 years after surgery. Taking into account the absolute risk difference of 93 more remissions per 1000 surgeries after RYGB shown in the present meta‐analysis and recent estimates of approximately 100 000 patients with diabetes undergoing bariatric surgery per year globally,[12](#obr13011-bib-0012){ref-type="ref"}, [13](#obr13011-bib-0013){ref-type="ref"} favouring RYGB over SG could result yearly in 9300 more cases with short‐term remission of diabetes.

4.2. Quality of evidence {#obr13011-sec-0022}
------------------------

We consider the quality of evidence from this systematic review to be moderate (short‐term follow‐up) to low (medium‐term follow‐up). The quality of evidence for studies with medium‐term follow‐up was downgraded for serious imprecision because of confidence intervals of the absolute effects being wide. Also, quality of evidence was downgraded one level for risk of bias as we considered risk of bias to be serious both for studies with short‐ and medium‐term follow‐up. Only one of the included trials was judged as having low risk of bias in all domains, and lack of blinding was the main culprit for down‐rating the studies. When studies with higher risk of bias were excluded from the analysis, the effect estimate increased in favour of RYGB. It is worrisome that the study by Ruiz‐Tovar et al,[30](#obr13011-bib-0030){ref-type="ref"} which was heavily weighted in our analyses, was registered in a clinical trial registry 2 weeks prior to publication of the results. The authors presented limited data on baseline characteristics and patient selection, and without the exact details as to how this study was conducted, it is difficult to assess potential biases.

4.3. Agreements and disagreements with other reviews {#obr13011-sec-0023}
----------------------------------------------------

In contrast with our results, a recently published meta‐analysis of RCTs[22](#obr13011-bib-0022){ref-type="ref"} reported no significant difference in the 1‐year remission rate of T2DM among patients undergoing RYGB compared with those undergoing SG. However, in this review, the landmark STAMPEDE trial[23](#obr13011-bib-0023){ref-type="ref"} and the RCT by Keidar et al were not included in the meta‐analysis of studies with 1‐year follow‐up.[24](#obr13011-bib-0024){ref-type="ref"}, [54](#obr13011-bib-0054){ref-type="ref"} This review also differed from the present review considering that other variants of gastric bypass, such as banded and mini gastric bypass,[41](#obr13011-bib-0041){ref-type="ref"}, [42](#obr13011-bib-0042){ref-type="ref"} were included, and understandably, it could not include the recently published results from the Oseberg‐trial.

Partly in contrast with our findings, another recent systematic review[25](#obr13011-bib-0025){ref-type="ref"} of RCTs concluded that there was no difference between RYGB and SG in T2DM resolution 1 to 5 years post surgery. However, this meta‐analysis did not include the results from the STAMPEDE trial[23](#obr13011-bib-0023){ref-type="ref"} and the study by Tang et al.[54](#obr13011-bib-0054){ref-type="ref"}

Our findings partly support the results of a previous meta‐analysis of 18 randomized and nonrandomized studies,[28](#obr13011-bib-0028){ref-type="ref"} which reported that patients undergoing RYGB had higher short‐ to long‐term odds (95% CI) (1.49 (1.04‐2.12), *P* = .03) of T2DM resolution than patients undergoing SG.

4.4. Strengths and limitations {#obr13011-sec-0024}
------------------------------

The present review was based on a broad literature search performed in cooperation with an expert librarian, and it is unlikely that important trials were overlooked. However, the number of studies included in the meta‐analyses were low, and the pooled estimates should be interpreted with caution. This review included studies of patients with similar characteristics (patients with T2DM eligible for bariatric surgery), and this is reflected in the low heterogeneity between the studies. Because of the low number of studies included in the meta‐analyses, we cannot exclude the possibility of publication bias. The definitions of remission of T2DM varied slightly between studies, some studies reported only data on partial remission, and seemingly small differences in glycaemic thresholds used to define diabetes remission may impact the proportions achieving remission, making comparisons between studies difficult.

5. CONCLUSION {#obr13011-sec-0025}
=============

The results from this systematic review show that RYGB resulted in a higher remission rate of T2DM after 1 year compared with SG. In studies with medium‐term follow‐up, there were no differences in T2DM remission rates between the two procedures; however, larger studies with longer term follow‐up are warranted.
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